SNCA and Parkinson disease: The treatment of a mouse model of chronic Parkinson’s disease with TUDCA indicated it has neuroprotective properties, including protection against dopaminergic neuronal damage, preventing microglial and astrocyte activation, reducing dopamine and its metabolite 3,4-dihydroxyphenylacetic acid, and inhibiting alpha-synuclein aggregation [61].